Design Therapeutics, Inc. DSGN
At closeNov 4, 2026, 4:00 PM EST
After hours · Nov 4, 4:00 PM ET
- YTD
- +13.33%
- 1 year
- +70.35%
- Market cap
- 665.24M
- EPS (ttm)
- -1.18
- Shares out
- 56.62M
- Forward P/E
- -5.13
- YTD return
- +13.33%
- 1-year return
- +70.35%
- Volume
- 314.98K
- Avg volume
- 581.50K
- Open
- 10.67
- Previous close
- 10.34
- Day's range
- 10.34 – 10.78
- 52-week range
- 6.23 – 17.25
- Beta
- 1.83
- Price target
- 7.00 (-34.1%)
- Earnings date
- Aug 5, 2024
5D -0.56 (-5.04%)
Key statistics
- Enterprise value
- 102.33M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.39
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -30.07M
- Total cash
- 254.07M
- Total debt
- 2.52M
- Return on equity
- -17.78%
- Short % of float
- 10.61%
- 50-day average
- 5.88
- 200-day average
- 4.63
Analyst view
- Target (low)
- 4.00
- Target (mean)
- 7.00
- Target (high)
- 12.00
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 5, 2024
Expected Aug 5, 2024. Consensus EPS estimate -0.26667.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.26 | -0.23 | +0.03 | +11.54% |
| Aug 5, 2024 | Jun 1, 2024 | -0.25 | -0.21 | +0.04 | +16.00% |
| Aug 5, 2024 | Jun 1, 2024 | -0.25 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.28 | -0.20 | +0.08 | +28.57% |
| May 8, 2024 | Mar 1, 2024 | -0.28 | — | — | — |
| Mar 19, 2024 | Dec 1, 2023 | -0.32 | -0.21 | +0.11 | +34.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| May 7, 2024 | Piper Sandler | up | Neutral | Overweight |
| Mar 20, 2024 | RBC Capital | reit | Sector Perform | Sector Perform |
| Mar 20, 2024 | Wedbush | reit | Neutral | Neutral |
| Nov 14, 2023 | RBC Capital | main | Sector Perform | Sector Perform |
| Aug 15, 2023 | Wedbush | down | Outperform | Neutral |
About Design Therapeutics, Inc.
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- designtx.com
News
Your note
Sign in to keep a note on DSGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERGER HEATHER A | Director | Purchase | Mar 24, 2024 | 1,300 |
| LAPPE RODNEY W | Director | Purchase | Sep 28, 2023 | 133,024 |
| PRASAD DEEPA | Director | Sale | Dec 17, 2024 | 20,000 |
| SCHMID JOHN P | Director | Purchase | Mar 24, 2024 | 0 |
| WILLIAM ARSANI H. | Director | Sale | Aug 8, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SR One Capital Management, LP | 11.53% | 6,526,476 | 40.53M | Sep 29, 2024 |
| Logos Global Management LP | 7.45% | 4,217,627 | 26.19M | Sep 29, 2024 |
| Blackrock Inc. | 4.17% | 2,358,797 | 14.65M | Sep 29, 2024 |
| Frazier Life Sciences Management, L.P. | 3.34% | 1,892,547 | 11.75M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 3.08% | 1,743,725 | 10.83M | Sep 29, 2024 |
| Point72 Asset Management, L.P. | 2.83% | 1,600,740 | 9.94M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 1.46% | 829,100 | 5.15M | Oct 30, 2024 |
| iShares Russell 2000 ETF | 1.43% | 809,268 | 5.03M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.41% | 800,901 | 4.97M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.71% | 399,505 | 2.48M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.57% | 320,414 | 1.99M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.52% | 292,403 | 1.82M | Oct 30, 2024 |